Current Research: Medical Oncology

E1697 -- Phase III Randomized Study of Four Weeks High Dose IFN-?2b in Stage T2b No, T3a-b No, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma

The incidence of melanoma is rising at a rate that exceeds that of all other neoplasms except for lung cancer in women.

The purpose of this trial is to compare the effect of treatment with 4 weeks of high dose IFN-alpha2b on the relapse free survival of intermediate risk melanoma patients.

Eligibility

You may be eligible for this trial if:

• You have undergone an adequate wide excision of the primary lesion
• You have completed all primary therapy (wide excision with or without lymphadenectomy) and can be randomized within 84 days of your wide excision.
• Melanoma of cutaneous origin are eligible
• Initial presentation of melanoma are eligible
• No clinical palpable lymphadenopathy
• T3N0M0, T4N0M0, or T1-4N1
• You may have other malignancies if you have been continuously disease free for 5 years prior to the time of randomization. Patients with any other history of invasive melanoma are not eligible.

Trial Sponsor

• Eastern Cooperative Oncology Group (ECOG)

Project Begin Date

• Dec 1999

Tentative Project End Date

• Dec 2014

Back to Medical Oncology Research

Revised March 30, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .